Daiken Medical Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	10,290	9,951	9,750	9,137	8,540
Revenue Growth (YoY)	3.41%	2.06%	6.71%	6.99%	8.64%
Cost of Revenue	6,340	5,855	5,768	5,607	4,856
Gross Profit	3,950	4,096	3,982	3,530	3,684
Selling, General & Admin	2,673	2,209	2,240	2,105	2,092
Research & Development	-	332	249	316	382
Operating Expenses	2,673	2,584	2,539	2,475	2,533
Operating Income	1,277	1,512	1,443	1,055	1,151
Interest Expense	-12	-9	-4	-3	-3
Interest & Investment Income	1	-	-	-	-
Currency Exchange Gain (Loss)	2	-	2	-	1
Other Non Operating Income (Expenses)	5	6	5	-	3
EBT Excluding Unusual Items	1,273	1,509	1,446	1,052	1,152
Gain (Loss) on Sale of Assets	-	-	2	-	-
Asset Writedown	-28	-2	-5	-28	-1
Other Unusual Items	-	-	-8	-	-
Pretax Income	1,245	1,507	1,435	1,024	1,151
Income Tax Expense	323	410	447	312	320
Net Income	922	1,097	988	712	831
Net Income to Common	922	1,097	988	712	831
Net Income Growth	-15.95%	11.03%	38.76%	-14.32%	23.11%
Shares Outstanding (Basic)	29	29	29	29	29
Shares Outstanding (Diluted)	29	29	29	29	29
EPS (Basic)	32.09	38.19	34.39	24.78	28.93
EPS (Diluted)	32.09	38.19	34.39	24.78	28.93
EPS Growth	-15.95%	11.03%	38.76%	-14.32%	23.11%
Free Cash Flow	240	954	1,393	791	931
Free Cash Flow Per Share	8.35	33.21	48.49	27.53	32.41
Gross Margin	38.39%	41.16%	40.84%	38.63%	43.14%
Operating Margin	12.41%	15.19%	14.80%	11.55%	13.48%
Profit Margin	8.96%	11.02%	10.13%	7.79%	9.73%
Free Cash Flow Margin	2.33%	9.59%	14.29%	8.66%	10.90%
EBITDA	1,535	1,744	1,657	1,322	1,465
EBITDA Margin	14.92%	17.53%	16.99%	14.47%	17.15%
D&A For EBITDA	258	232	214	267	314
EBIT	1,277	1,512	1,443	1,055	1,151
EBIT Margin	12.41%	15.19%	14.80%	11.55%	13.48%
Effective Tax Rate	25.94%	27.21%	31.15%	30.47%	27.80%